Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hitoshi Ohno

Showing results (111-120 of 113) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 113 results.
Annals of Nuclear Medicine|March 19, 2013
Observer variation study of the assessment and diagnosis of incidental colonic FDG uptakeRyogo Minamimoto, Takashi Terauchi, Seishi Jinnouchi, et al.
International Journal of Hematology|November 16, 2010
Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305)Michinori Ogura, Kuniaki Itoh, Tomohiro Kinoshita, et al.
Hematology (Amsterdam, Netherlands)|February 14, 2022
Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trialHiroyuki Muranushi, Junya Kanda, Masayuki Kobayashi, et al.
Pageof 12

Showing results (111-120 of 113) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 113 results.
Annals of Nuclear Medicine|March 19, 2013
Observer variation study of the assessment and diagnosis of incidental colonic FDG uptakeRyogo Minamimoto, Takashi Terauchi, Seishi Jinnouchi, et al.
International Journal of Hematology|November 16, 2010
Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305)Michinori Ogura, Kuniaki Itoh, Tomohiro Kinoshita, et al.
Hematology (Amsterdam, Netherlands)|February 14, 2022
Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trialHiroyuki Muranushi, Junya Kanda, Masayuki Kobayashi, et al.
Pageof 12